THE European Medicines Agency has announced a public hearing into quinolone and fluoroquinolone antibiotics, giving a "voice to patients, doctors, nurses, pharmacists, researchers and everyone else" who wants to share their experience with using the medications.
Quinolones and fluoroquinolones are widely prescribed in the European Union, and the hearing is part of a review being carried out by EMA's Pharmacovigilance Risk Assessment Committee which is investigating reports of "serious persistent side effects" mainly affecting muscles, joints and the nervous system.
Some of the effects have been reported in patients with infections that were not severe and could have been treated with other antibiotics, the EMA said.
The session will take place at the agency's current London premises on 13 Jun 208 - ec.europa.eu.
The above article was sent to subscribers in Pharmacy Daily's issue from 10 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Apr 18
